Aliskiren: The first direct renin inhibitor for hypertension

Current Cardiology Reports

Volumn 9, Issue 6, 2007, Pages 470-476

  van den Meiracker, Anton H ^b   Danser, A H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; PLACEBO; PRORENIN; PRORENIN RECEPTOR; RAMIPRIL; RECEPTOR; RENIN; RENIN INHIBITOR; UNCLASSIFIED DRUG; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; MONOTHERAPY; NONHUMAN; PHARMACODYNAMICS; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINGLE DRUG DOSE; UNITED STATES;

AMIDES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FUMARATES; HUMANS; HYPERTENSION; RECEPTORS, CELL SURFACE; RENIN; RENIN-ANGIOTENSIN SYSTEM; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 36048948227     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02938391     Document Type: Review

References (50)

1. Danser AHJ: Local renin-angiotensin systems: the unanswered questions. Int J Biochem Cell Biol 2003, 35:759-768.
2. van Kats JP, Schalekamp MA, Verdouw PD, et al.: Intrarenal angiotensin II: interstitial and cellular levels and site of production. Kidney Int 2001, 60:2311-2317.
3. van Kars JP, Chai W, Duncker DJ, et al.: Adrenal angiotensin: origin and site of generation. Am J Hypertens 2005, 18:1104-1110.
4. Campbell DJ, Kladis A, Duncan AM: Nephrectomy, converting enzyme inhibition, and angiotensin peptides. Hypertension 1993, 22:513-522.
5. Klotz S, Foronjy RF, Dickstein ML, et al.: Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness. Circulation 2005, 112:364-374.
6. van Esch JH, Tom B, Dive V, et al.: Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction. Hypertension 2005, 45:120-125.
7. Batenburg WW, Garrelds IM, Bernasconi CC, et al.: Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation 2004, 109:2296-2301.
8. Tom B, Garrelds IM, Scalbert E, et al.: ACE-versus chymase-dependent angiotensin II generation in human coronary arteries: a matter of efficiency? Arterioscler Thromb Vasc Biol 2003, 23:251-256.
9. Chai W, Garrelds IM, de Vries R, et al.: Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II. Hypertension 2005, 46:701-706.
10. Danser AHJ, van Kats JP, Admiraal PJ, et al.: Cardiac renin and angiotensins: uptake from plasma versus in situ synthesis. Hypertension 1994, 24:37-48.
11. Danser AHJ, van Kesteren CAM, Bax WA, et al.: Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts: evidence for renin binding. Circulation 1997, 96:220-226.
12. Danser AHJ, Derkx FH, Schalekamp MA, et al.: Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens 1998, 16:853-862.
13. Azizi M, Bissery A, Lamarre-Cliche M, Ménard J: Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans. Hypertension 2004, 43:785-790.
14. Mooser V, Nussberger J, Juillerat L, et al.: Reactive hyper-reninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990, 15:276-282.
15. Schalekamp MA, Danser AHJ: Angiotensin II production and distribution in the kidney: I. A kinetic model. Kidney Int 2006, 69:1543-1552.
16. Schalekamp MA, Danser AHJ: Angiotensin II production and distribution in the kidney: II. Model-based analysis of experimental data. Kidney Int 2006, 69:1553-1557.
17. de Lannoy LM, Schuijt MP, Saxena PR, et al.: Angiotensin-converting enzyme is the main contributor to angiotensin I-II conversion in the interstitium of isolated perfused rat heart. J Hypertens 2001, 19:959-965.
18. Schuijt MP, de Vries R, Saxena PR, et al.: Vasoconstriction is determined by interstitial rather than circulating angiotensin II. Br J Pharmacol 2002, 135:275-283.
19. van den Eijnden MM, de Bruin RJ, de Wit E, et al.: Transendothelial transport of renin-angiotensin system components. J Hypertens 2002, 20:2029-2037.
20. Fisher ND, Hollenberg NK: Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol 2005, 16:592-599.
21. Nguyen G, Delarue F, Burcklé C, et al.: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002, 109:1417-1427.
22. Danser AHJ, Deinum J: Renin, prorenin and the putative (pro)renin receptor. Hypertension 2005, 46:1069-1076.
23. Sealey JE, Moon C, Laragh JH, Atlas SA: Plasma prorenin in normal, hypertensive, and anephric subjects and its effect on renin measurements. Circ Res 1977, 40(Suppl 1):141-145.
24. Itskovitz J, Sealey JE, Glorioso N, Rosenwaks Z: Plasma prorenin response to human chorionic gonadotropin in ovarian-hyperstimulated women: correlation with the number of ovarian follicles and steroid hormone concentrations. Proc Natl Acad Sci USA 1987, 84:7285-7289.
25. Derkx FH, Alberda AT, de Jong FH, et al.: Source of plasma prorenin in early and late pregnancy: observations in a patient with primary ovarian failure. J Clin Endocrinol Metab 1987, 65:349-354.
26. Danser AHJ, van den Dorpel MA, Deinum J, et al.: Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 1989, 68:160-167.
27. Clausmeyer S, Sturzebecher R, Peters J: An alternative transcript of the rat renin gene can result in a truncated prorenin that is transported into adrenal mitochondria. Circ Res 1999, 84:337-344.
28. Nussberger J: Circulating versus tissue angiotensin II. In Angiotensin II Receptor Antagonists. Edited by Epstein M, Brunner HR, eds. Philadelphia: Hanley & Belfus, Inc.; 2000:69-78.
29. Saris JJ, Derkx FH, de Bruin RJ, et al.: High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes proteolytic activation to renin. Am J Physiol Heart Circ Physiol 2001, 280:H1706-H1715.
30. Ichihara A, Hayashi M, Kaneshiro Y, et al.: Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 2004, 114:1128-1135.
31. Ichihara A, Kaneshiro Y, Takemitsu T, et al.: Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 2006, 47:894-900.
32. Ichihara A, Suzuki F, Nakagawa T, et al.: Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type la receptor-deficient mice. J Am Soc Nephrol 2006, 17:1950-1961.
33. van Esch JH, Schuijt MP, Sayed J, et al.: AT2 receptor-mediated vasodilation in the mouse heart depends on AT1A receptor activation. Br J Pharmacol 2006, 148:452-458.
34. Huang Y, Wongamorntham S, Kasting J, et al.: Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006, 69:105-113.
35. Saris JJ, 't Hoen PA, Garrelds IM, et al.: Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension 2006, 48:564-571.
36. Burcklé CA, Danser AHJ, Müller DN, et al.: Elevated blood pressure and heart rate in human renin receptor transgenic rats. Hypertension 2006, 47:552-556.
37. Kaneshiro Y, Ichihara A, Takemitsu T, et al.: Increased expression of cyclooxygenase-2 in the renal cortex of human prorenin receptor gene-transgenic rats. Kidney Int 2006, 70:641-646.
38. Schefe JH, Menk M, Reinemund J, et al.: A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res 2006, 99:1355-1366.
39. Azizi M, Webb R, Nussberger J, Hollenberg NK: Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006, 24:243-256.
40. Nussberger J, Wuerzner G, Jensen C, Brunner HR: Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2002, 39:E1-E8.
41. Vaidyanathan S, Warren V, Yeh C, et al.: Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol 2007, 47:192-200.
42. Azizi M, Ménard J, Bissery A, et al.: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotcnsin II-renin feedback interruption. J Am Soc Nephrol 2004, 15:3126-3133.
43. Villamil A, Chrysant SG, Calhoun D, et al.: Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007, 25:217-226.
44. Jordan J, Engeli S, Boye SW, et al.: Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007, 49:1047-1055
45. O'Brien E, Barton J, Nussberger J, et al.: Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007, 49:276-284.
46. Pool JL, Schmieder RE, Azizi M, et al.: Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007, 20:11-20.
47. Gradman AH, Schmieder RE, Lins RL, et al.: Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005, 111:1012-1018.
48. Oh BH, Mitchell J, Herron JR, et al.: Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007, 49:1157-1163.
49. Stanton A, Jensen C, Nussberger J, O'Brien E: Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003, 42:1137-1143.
50. Kushiro T, Itakura H, Abo Y, et al.: Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006, 29:997-1005.